← Back to Search

Unknown

CBL-514 Injections for Cellulite

Phase 2
Waitlist Available
Research Sponsored by Caliway Biopharmaceuticals Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks from the final treatment visit
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing CBL-514, a treatment given through skin injections, in people with a specific type of cellulite that may not respond to usual treatments. The goal is to see if these injections can safely and effectively reduce cellulite.

Who is the study for?
This trial is for women aged 18-64 with a certain level of cellulite, known as EFP (Stage 2), who have stable lifestyles and body weight requirements. They must not be on certain medications or have conditions that could affect the study's safety or results, like liver issues, cardiovascular diseases, or recent aesthetic procedures. Participants cannot be pregnant and must use contraception.
What is being tested?
The trial is testing CBL-514 injections to see if they are effective and safe in treating Stage 2 cellulite. It's an open-label study where all participants receive the treatment without being compared to a placebo or other treatments.
What are the potential side effects?
While specific side effects of CBL-514 aren't listed here, common injection-related side effects may include pain at the injection site, swelling, bruising, redness, itching and potential allergic reactions to ingredients.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks from the final treatment visit
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks from the final treatment visit for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Evaluation of the score change of edematous fibrosclerotic panniculopathy (EFP) measured by cellulite severity scale from baseline following administration of at least 1 course of CBL-514.
Secondary study objectives
Evaluation of the response rate of EFP score change by Global Aesthetic Improvement Scale (GAIS) reported by the clinician and participant, respectively, following the administration of at least 1 course of CBL-514.
Evaluation of the total score change of edematous fibrosclerotic panniculopathy (EFP) measured by cellulite severity scale from baseline following administration of at least 1 course of CBL-514.
Percentage of participants' thighs that achieve at least 1-level severity improvement measured by cellulite severity scale from baseline following administration of 1 course of CBL-514.
+1 more
Other study objectives
Incidence of adverse events and treatment-emergent adverse events (TEAEs)
Incidence of adverse events and treatment-emergent adverse events (TEAEs) at the injection site(s)
Incidence of adverse events and treatment-emergent adverse events (TEAEs) related to the investigational product (IP)
+4 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: CBL-514 up to 320mgExperimental Treatment1 Intervention
Participants will receive up to 320 mg per treatment session at intervals of approximately 4 weeks for up to a maximum of 2 treatments.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CBL-514 injection
2023
Completed Phase 2
~30

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for cellulite include topical treatments, laser and radiofrequency therapy, and injectable treatments. Topical treatments often contain ingredients like caffeine or retinol, which aim to improve skin texture and reduce fat cells. Laser and radiofrequency therapies work by heating the skin and underlying tissues to stimulate collagen production and break down fat. Injectable treatments, such as CBL-514, typically involve substances that break down fat cells and improve skin elasticity. Understanding these mechanisms is crucial for patients as it helps them make informed decisions about which treatment may be most effective for their specific condition and expectations.
Does Hyperbaric Oxygenation Improve Athletic Performance?Exercise therapy for sarcopenia in rheumatoid arthritis: A meta-analysis and meta-regression of randomized controlled trials.SARCOPENIA IN PRIMARY CARE: SCREENING, DIAGNOSIS, MANAGEMENT.

Find a Location

Who is running the clinical trial?

Caliway Biopharmaceuticals Co., Ltd.Lead Sponsor
10 Previous Clinical Trials
527 Total Patients Enrolled
1 Trials studying Cellulite
12 Patients Enrolled for Cellulite
Anne SheuStudy DirectorCaliway Biopharmaceuticals Co., Ltd.
6 Previous Clinical Trials
389 Total Patients Enrolled
1 Trials studying Cellulite
12 Patients Enrolled for Cellulite
~9 spots leftby Nov 2025